Chemotherapy-induced nausea and vomiting represent 82.5% of application sales and powder accounts for 76.0% within the form segment in 2026. The aprepitant market was valued at USD 68.94 million in 2025, is projected to reach USD 132.16 million by 2036 and is forecast to post a 6.04% CAGR between 2026 and 2036.